Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
A Phase 1 Study of Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer Before or After Progression on Docetaxel.
Sponsor: Astellas Pharma Inc
Listed as NCT02207504, this PHASE1 trial focuses on Castration-resistant Prostate Cancer and remains completed. Sponsored by Astellas Pharma Inc, it has been updated 12 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Feb 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
May 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE1
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting PHASE1
▶ Show 7 earlier versions
-
May 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
-
Apr 2020 — May 2020 [monthly]
Active Not Recruiting PHASE1
-
Mar 2019 — Apr 2020 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Aug 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Inc
- Dana-Farber Cancer Institute
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .